Post-COVID-19 Condition as a Mass Disabling Event: Unifying Pathophysiology, Clinical Phenotypes, and the "Treatable Traits" Approach
,, B., Yameen, S., Tasleem, M., Rajpoot, S. (2025). Post-COVID-19 Condition as a Mass Disabling Event: Unifying Pathophysiology, Clinical Phenotypes, and the "Treatable Traits" Approach. EKB Journal Management System, 23(2), 41-50. doi: 10.21608/ejpa.2025.408624.1091
Bhagvanti ,; Samira Yameen; Muhammad Wasim Tasleem; Sehrish Rana Rajpoot. "Post-COVID-19 Condition as a Mass Disabling Event: Unifying Pathophysiology, Clinical Phenotypes, and the "Treatable Traits" Approach". EKB Journal Management System, 23, 2, 2025, 41-50. doi: 10.21608/ejpa.2025.408624.1091
,, B., Yameen, S., Tasleem, M., Rajpoot, S. (2025). 'Post-COVID-19 Condition as a Mass Disabling Event: Unifying Pathophysiology, Clinical Phenotypes, and the "Treatable Traits" Approach', EKB Journal Management System, 23(2), pp. 41-50. doi: 10.21608/ejpa.2025.408624.1091
,, B., Yameen, S., Tasleem, M., Rajpoot, S. Post-COVID-19 Condition as a Mass Disabling Event: Unifying Pathophysiology, Clinical Phenotypes, and the "Treatable Traits" Approach. EKB Journal Management System, 2025; 23(2): 41-50. doi: 10.21608/ejpa.2025.408624.1091

Post-COVID-19 Condition as a Mass Disabling Event: Unifying Pathophysiology, Clinical Phenotypes, and the "Treatable Traits" Approach

The Egyptian Journal of Pediatric Allergy and Immunology
Volume 23, Issue 2, October 2025, Pages 41-50    PDF (532.56 K)
Document Type: Review
DOI: 10.21608/ejpa.2025.408624.1091
Authors
Bhagvanti ,1; Samira Yameen2; Muhammad Wasim Tasleem* 3; Sehrish Rana Rajpoot4
1Department of Zoology, Federal Urdu University of Arts, Science and Technology (Gulshan-E- Iqbal Campus), Karachi
2Department of Physiology, University of Karachi
3Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Pakistan.
4University College of Conventional Medicine, Islamia University Bahawalpur, Pakistan
Abstract
Background: Post-COVID-19 Condition (PCC), or Long COVID, affects 10-20% of SARS-CoV-2 survivors, emerging as a significant global health challenge and a mass disabling event due to its persistent and heterogeneous symptoms. We sought to synthesize current evidence on PCC’s pathophysiology, delineate its major clinical phenotypes, and propose a personalized treatment framework. Methods: A review of recent literature was conducted, focusing on pathophysiological mechanisms (viral persistence, immune dysregulation, endothelial dysfunction, neurological disruptions) and clinical phenotyping from large-scale studies like National Institutes of Health (NIH) RECOVER. Results: PCC exhibits profound clinical heterogeneity, with major phenotypes including fatigue-dominant, neurocognitive, cardiopulmonary, and dysautonomia-related clusters. Core pathophysiological pillars include viral persistence, immune dysregulation, endothelial dysfunction, and neurological disruptions. The proposed "treatable traits" model targets specific pathophysiological traits (e.g., micro thrombosis, mast cell activation) for personalized diagnostics and therapies. Conclusion: The "treatable traits" model offers a roadmap for shifting PCC management from symptomatic relief to mechanism-based care, guiding effective treatment and future research to address this global disability crisis.
Keywords
Post-COVID-19 Condition; Long COVID; Pathophysiology; Treatable Traits; Viral Persistence
Statistics
Article View: 9
PDF Download: 5